Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
* Total revenues increased by 50% to 19.7 million euro (2004: 13.1 million euro) * Operating loss (EBIT) reduced by 22% to -11.5 million euro (2004: -14.7 million euro) * Forecast 2006: further...
MARTINSRIED, Germany and SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- The Executive Board of the German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG, TecDAX) has decided...
- MediGene Receives Milestone Payment for Launch in France - MediGene's First Drug* Now Available in 11 European Countries MARTINSRIED, Germany and SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/...
MARTINSRIED/MUNICH, Germany and SAN DIEGO, Feb. 14 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (German Stock Exchange (Frankfurt), Prime Standard: MDG) (MDGGn.DE...
* Bradley acquires US commercialization rights for genital warts and other dermatological diseases. MediGene retains full rest of world commercialization rights. MARTINSRIED, Germany and MUNICH...
* A non-exclusive license under existing tumor-vaccine patents MARTINSRIED, Germany and MUNICH, Germany, and SAN DIEGO, Dec. 19 /PRNewswire-FirstCall/ -- The German-American biotech company...
MARTINSRIED and MUNICH, Germany and SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (Frankfurt, Germany; TecDAX) [MDGEF.PK] announces today that the...
* Total revenues of 8.6 million euro (9M-2004: 11.5 million euro) MARTINSRIED/MUNICH, Germany and SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- - Today the German-American biotech company MediGene...
MARTINSRIED, Germany and SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Today the German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announced the initiation of a phase...
* Total revenues of 4.9 million euro (H1-2004: 8.8 million euro) * Net loss -6.3 million euro (H1-2004: -4.2 million euro) * Operational cash flow -6.6 million euro (H1-2004: -4.3 Mio. euro...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.295 | 1.295 | 1.295 | 0 | 0 | CS |
| 26 | -3.565 | -73.353909465 | 4.86 | 4.86 | 1.295 | 260 | 2.33326059 | CS |
| 52 | -1.805 | -58.2258064516 | 3.1 | 5.68 | 1.295 | 337 | 3.54425606 | CS |
| 156 | -5.615 | -81.2590448625 | 6.91 | 8.8 | 1.295 | 1045 | 4.55281485 | CS |
| 260 | -8.205 | -86.3684210526 | 9.5 | 15.2198 | 1.295 | 1491 | 8.46889897 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| AITXArtificial Intelligence Technology Solutions Inc (PK) | US$ 0,00275 (0,00%) | 51,06M |
| GTEHGenTech Holdings Inc (CE) | US$ 0,000001 (0,00%) | 48,25M |
| HMBLHUMBL Inc (PK) | US$ 0,0002 (-33,33%) | 42,65M |
| CBGLCannabis Global Inc (PK) | US$ 0,00015 (50,00%) | 41,81M |
| GTVHGolden Triangle Ventures Inc (PK) | US$ 0,0008 (33,33%) | 41,61M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
